Several clinical trials of metabolic pharmacotherapies for the treatment of NASH including farnesoid X receptor (FXR) agonists (obeticholic acid) (NCT02548351, NCT03439254), PPARα and PPARδ agonists (elafibranor) (NCT02704403), glucagon-like peptide (GLP)-1 (semaglutide) (NCT02970942) have been studied. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.